Absence of operational manual that guides examiners, heavy backlog take a toll.
Indian pharmaceutical companies exporting medicines worth $1 billion to at least a dozen countries like Brazil, Mexico, China and Germany are finding non-tariff barriers, in the form of discriminatory treatments, hampering their export prospect.
The proposed India-Iran Double Taxation Avoidance Agreement, which the two countries included in their joint New Delhi declaration in 2003, has run into a hurdle.
Besides Novartis, the other companies are Roche, J&J, Glaxo and Astrazeneca.
Defence officials contend that the services do not use spectrum for 'commercial purposes' and therefore do not need to pay for it.
This has prompted public health groups to call the concerns of Swiss drug major Novartis that inadequacies in Indian patent law will have negative consequences for patients and public health in India as 'bogus'.
The government is considering a proposal to examine foreign direct investment applications on a sector-wise, rather than country-wise, basis to assess their threat to national security.
Move could delay FDI liberalisation in the sector.
The central government is considering an expansion of the list of fertilisers that are eligible for subsidy.
Contrary to the income tax department's hopes, many taxpayers continue to attach annexures (documents like tax deducted at source certificates etc) with the so-called annexure-less tax return forms introduced from this year.
Rs 35,000 crore investment to increase capacity by 75%.
The railway ministry has decided to sell a 20 per cent stake in RITES Ltd, an undertaking of the ministry which, among other activities, operates railway networks in some African countries, in an initial public offer.
Mohit Burman, the youngest among the newly appointed corporate heads among Dabur businesses, is known to have a penchant for acquisitions.
Interestingly, the allegations against Indian arm of the world's largest pharma maker also relates to its acquisition of the Indian subsidiary of Parke Davis by Pfizer in 2000.
Individual scientists attached to research institutions and domestic companies like Lupin, Dr Reddy's and Cadila account for the rest.
Drug banks, cancer fund now health ministry's babies.
This year's projected increase in per capita (in dollar terms) is nearly double the average 13 per cent growth between 2003-04 and 2006-07.
Tops the group in mobile voice usage volumes.
The whole order had included both 2G, the currently used technology, and third generation lines (used for high-speed mobile Internet access).
Indian companies are unable to raise prices because 35 per cent of the drugs sold in the country come under the government's price control order.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances